Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

egulatory approvals, the terms of any product approval, including labeling, may be more restrictive than desired and could affect the marketability of its products. Regulatory authorities also have the power amongst other things, to:

    - revoke or suspend approvals of previously approved products;

    - require the recall of products that fail to meet regulatory
      requirements; and

    - close manufacturing plants that do not operate in conformity
      with cGMP and/or other regulatory requirements or approvals.

Such delays or actions could affect the Group's ability to manufacture and sell its products.

The failure of a strategic partner to develop and commercialize products could result in delays in approval or loss of revenue

The Group enters into strategic partnerships with other companies in areas such as product development and sales and marketing. In these partnerships, the Group is dependent on its partner to deliver results. While these partnerships are supported by contracts, the Group does not exercise direct control. If a partner fails to perform or experiences financial difficulties, the Group may suffer a delay in the development, a delay in the approval or a reduction in sales or royalties of a product.

The failure to secure new products or compounds for development, either through in-licensing, acquisition or internal research and development efforts, may have an adverse impact on the Group's future results

The Group's future results will depend, to a significant extent, upon its ability to in-license, acquire or develop new products or compounds. The Group also expends significant resources on research and development. The failure to in-license or acquire new products or compounds, on a commercially viable basis, could have a material adverse effect on the Group's financial position. The failure of these efforts to result in the d
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 24, 2014 The report ... at 19.7% by 2019. It also provides a carefully ... strategies and challenges for the market. , Full Copy ... the report, the global market for cell expansion will ... future. It expects this growth to be driven by ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 23, 2014 /PRNewswire/ ... solutions company focused on gynecologic disease, announced today ... W. Schuler , Birchview Fund LLC and several ... million of unregistered shares of Vermillion,s common stock ... common stock in a private placement.  ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
(Date:12/22/2014)... Md. , Dec. 22, 2014 /PRNewswire/ ... SYN), a developer of pathogen-specific therapies for ... on protecting the microbiome, today announced positive ... Phase 1a clinical trial of SYN-004, the ... prevention of Clostridium difficile (C. difficile) ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... 16 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that ... with Abbott for the exclusive worldwide development and commercialization of elagolix and the ... , The live ... at 8:45 a.m. Eastern Time ( 5:45 a.m. Pacific Time ...
... ... for certifying dentists in a new denture retention system procedure that can add 20% profit to ... (PRWEB) June 16, ... in a new denture retention system procedure that can add 20% profit to a ...
... American ... ... Association named medical writer, Rita Buckley, Writer/Owner of medical writing firm Buckley/Swartz, ... the awards for The Lehman Series Expert Panel on Weight Loss Surgery, published in ...
Cached Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix 2Summit Dental Institute Offers A Hands-On One-Day Imtec MDI Mini Dental Implant Certification Course For Dentists 2Summit Dental Institute Offers A Hands-On One-Day Imtec MDI Mini Dental Implant Certification Course For Dentists 3Summit Dental Institute Offers A Hands-On One-Day Imtec MDI Mini Dental Implant Certification Course For Dentists 4Medical Writer Rita Buckley Wins Awards for Excellence in Medical Communication 2Medical Writer Rita Buckley Wins Awards for Excellence in Medical Communication 3
(Date:12/3/2014)... , Dec. 2, 2014   Marvin ... deployed, innovative test solutions for military, aerospace, and ... version of its successful TS-900 PXI semiconductor ... and features of high-end systems to customers at ... value compared to traditional ATE. ...
(Date:11/21/2014)... , Nov. 20, 2014 Strict laws against ... are piloting the North American and European automotive sector ... growing, gesture recognition systems that are intuitive and able ... in the industry. New analysis from ... Recognition Market in Europe and ...
(Date:11/18/2014)...   News Highlights: ... The Partners Data Lake, an agile data and ... will allow researcher and clinicians to explore and ... lives of patients , The Partners Data ... the Partners system, breaking down physical barriers for ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... vital component of good health. Like plants that thrive in ... case for the production of vitamin D. In the past ... sun exposure. From fear of the potential dangers of UV ... work and recreational environments centered on virtual reality, we are ...
... 19 March 2009 World Water Day on Sunday, ... increasing scarcity of clean drinking water on our planet. ... causing more damage than ever before. Helmholtz scientists ... on solutions to precisely these problems. In cooperation with ...
... for Science Writings at Stevens Institute of Technology will host ... a talk by Bernd Heinrich, on Wednesday, April 1, 2009. ... 122, from 4 p.m. to 5:30 p.m. The journalist ... naturalist writer; he,s a great writer, period." A professor emeritus ...
Cached Biology News:The sunlight solution for better health 2The sunlight solution for better health 3Research to secure a safe water supply 2Research to secure a safe water supply 3Research to secure a safe water supply 4
... a chromogenic medium for the detection, ... (except S. thyphi) and total coliforms ... takes a maximum of 24 hours, ... sterilization during preparation and performs a ...
Large-capacity refrigerated incubator chamber holds up to 4 independently-operated shakers. Programmable heat, refrigeration, humidifcation are standard. Photosynthetic operation, optional....
...
... The Pulsed Dynamic Focusing MALDI (PDF-MALDI) source ... samples that do not need online separation. ... Trap LC/MS and Agilents powerful Spectrum Mill ... fast analysis of 2D gel-spot digests. It ...
Biology Products: